Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-100
Closed -$12.6K 1214
2025
Q2
$12.6K Sell
100
-25,100
-100% -$3.13M ﹤0.01% 1289
2025
Q1
$3.45M Buy
25,200
+24,800
+6,200% +$3.55M 0.14% 201
2024
Q4
$61.2K Sell
400
-17,900
-98% -$3.02M ﹤0.01% 1091
2024
Q3
$3.55M Sell
18,300
-15,300
-46% -$3.2M 0.12% 214
2024
Q2
$7.79M Buy
33,600
+32,000
+2,000% +$6.95M 0.28% 87
2024
Q1
$345K Buy
+1,600
New +$375K 0.01% 838

Other funds holding BIIB

Point72 (DIFC)'s BIIB Position: Q3 2025 in Review

Point72 (DIFC) reduced its Biogen (BIIB) stake by 95% in Q3 2025, selling an estimated $2.1M and leaving 772 shares worth $108K. The position accounts for 0.01% of the portfolio, ranked #563.

Point72 (DIFC) first reported a position in BIIB in Q1 2024 and has held it in 5 quarters since. The position peaked at $6.82M in Q1 2025. 908 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

  • Point72 (DIFC) held 772 shares of Biogen worth $108K as of Q3 2025.
  • Point72 (DIFC) sold 15,529 Biogen shares in Q3 2025, an estimated $2.1M.
  • Biogen made up 0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #563 holding.
  • Point72 (DIFC) first reported a position in Biogen in Q1 2024 and has held it in 5 quarters since.
  • Point72 (DIFC)'s Biogen position peaked at $6.82M in Q1 2025.
  • 908 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.